ClinicalTrials.Veeva

Menu

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

R

Resolve Therapeutics

Status and phase

Completed
Phase 1

Conditions

Systemic Lupus Erythematosus

Treatments

Biological: RSLV-132

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.

Enrollment

32 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stable SLE with no anticipated change in medications for the next 60 days

Exclusion criteria

  • Other biologic drugs

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

32 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Saline infusion
Treatment:
Biological: RSLV-132
RSLV-132
Experimental group
Description:
0.3 - 10 mg/kg experimental drug
Treatment:
Biological: RSLV-132

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems